Canaccord analyst Whitney Ijem lowered the firm’s price target on Verve Therapeutics to $30 from $32 and keeps a Buy rating on the shares. The firm said the 4Q earnings report was uneventful with pipeline updates largely on track.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VERV: